华森制药控股股东半个月减持315.82万股 套现5495万元

Core Viewpoint - Chengdu Dijiang, the controlling shareholder of Huason Pharmaceutical, has reduced its shareholding due to funding needs, but this change will not affect the company's control or ongoing operations [1][3]. Shareholding Changes - Before the recent changes, Chengdu Dijiang and its concerted parties held a total of 287,123,875 shares, accounting for 68.76% of the total share capital. After the reduction, they now hold 283,965,675 shares, which is 68.00% of the total [1][2]. - The reduction involved selling 948,400 shares through centralized bidding and 2,209,800 shares through block trading, totaling 3,158,200 shares sold [1][2]. Financial Performance - In 2024, Huason Pharmaceutical reported a revenue of 775 million yuan, a year-on-year increase of 12.04%. The net profit attributable to shareholders was approximately 76.73 million yuan, up 134.66% compared to the previous year [4][5]. - The net cash flow from operating activities was 161.77 million yuan, showing a decline of 26.25% year-on-year [4][5]. - Basic earnings per share increased to 0.1837 yuan, reflecting a growth of 134.61% [4][5]. Shareholding Structure - The shareholding structure indicates that Chengdu Dijiang holds 41.24% of the shares as unrestricted, while 17.34% are under restricted conditions. The total number of shares held by Chengdu Dijiang and its concerted parties has decreased from 290,472,175 shares (69.56%) to 283,965,675 shares (68.00%) [2][3].